EHAB 📈 Enhabit - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022
EHAB: Home Health, Hospice Services
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas. Web URL: https://www.ehab.com
Additional Sources for EHAB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EHAB Stock Overview
Market Cap in USD | 383m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2022-07-01 |
EHAB Stock Ratings
Growth 5y | -81.9% |
Fundamental | -51.2% |
Dividend | - |
Rel. Strength Industry | -633 |
Analysts | 3/5 |
Fair Price Momentum | 5.81 USD |
Fair Price DCF | 27.27 USD |
EHAB Dividends
No Dividends PaidEHAB Growth Ratios
Growth Correlation 3m | 48.5% |
Growth Correlation 12m | -79.9% |
Growth Correlation 5y | -90.6% |
CAGR 5y | -37.66% |
CAGR/Mean DD 5y | -0.70 |
Sharpe Ratio 12m | -0.44 |
Alpha | -45.12 |
Beta | 0.57 |
Volatility | 64.22% |
Current Volume | 814.9k |
Average Volume 20d | 452.8k |
What is the price of EHAB stocks?
As of December 22, 2024, the stock is trading at USD 7.65 with a total of 814,876 shares traded.
Over the past week, the price has changed by -10.21%, over one month by +2.55%, over three months by -4.97% and over the past year by -27.42%.
As of December 22, 2024, the stock is trading at USD 7.65 with a total of 814,876 shares traded.
Over the past week, the price has changed by -10.21%, over one month by +2.55%, over three months by -4.97% and over the past year by -27.42%.
Is Enhabit a good stock to buy?
No, based on ValueRay Fundamental Analyses, Enhabit (NYSE:EHAB) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -51.21 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EHAB as of December 2024 is 5.81. This means that EHAB is currently overvalued and has a potential downside of -24.05%.
No, based on ValueRay Fundamental Analyses, Enhabit (NYSE:EHAB) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -51.21 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EHAB as of December 2024 is 5.81. This means that EHAB is currently overvalued and has a potential downside of -24.05%.
Is EHAB a buy, sell or hold?
Enhabit has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold EHAB.
Enhabit has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold EHAB.
- Strong Buy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecast for EHAB stock price target?
According to ValueRays Forecast Model, EHAB Enhabit will be worth about 6.3 in December 2025. The stock is currently trading at 7.65. This means that the stock has a potential downside of -18.04%.
According to ValueRays Forecast Model, EHAB Enhabit will be worth about 6.3 in December 2025. The stock is currently trading at 7.65. This means that the stock has a potential downside of -18.04%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.7 | 13.1% |
Analysts Target Price | 11.1 | 44.8% |
ValueRay Target Price | 6.3 | -18% |